Skip to main content

Table 3 Costs, outcomes and ICERs compared to DTG + ABC/3TC

From: Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

 Treatment naïveFirst line failures
DTG + TDF/3TCEFV + TDF/3TCDTG + TDF/3TCLPV/r + TDF/3TC
Efficacy
 Responders (%)75.364.074.858.4
 Months of response41.736.741.433.7
 Life years4.7284.7284.7284.728
 QALYs4.2324.2274.2244.221
Costs (in RMB)
 Total219,259221,605238,746244,364
 ART24,74411,95824,74424,744
 Routine care173,930184,364187,859192,237
 AEs and other events13,29713,35713,09213,182
 Indirect costs728911,92613,05214,202
ICERs (including indirect costs)
 Costs/responderDTG dominatesDTG dominates
 Costs/QALYDTG dominatesDTG dominates
ICERs (excluding indirect costs)
 Costs/responderDTG dominatesDTG dominates
 Costs/QALYDTG dominatesDTG dominates